Lifeboat Foundation

The updates don’t come every spring and fall, but space operating systems keep evolving.

Every human being is home to trillions of microbes that are collectively known as the microbiota. Recent research into how these microbes affect the immune system may explain why older people are more vulnerable to disease and suggest ways to tackle that vulnerability.

Scientists at The University of Edinburgh’s Roslin Institute, led by Professor Neil Mabbott, discovered that as mice get older they showed a marked decrease in the number of M cells found in the lining of the gut. These are specialised cells that look out for infections and trigger the early stages of the immune response. Fewer M cells means a weaker immune system. At the same time, the researchers found that the older mice had depleted microbiota compared to younger mice. The microbiota were less diverse and certain species known to decrease inflammation of the gut in humans were missing.

Turbulent Past

Several companies and teams of scientists have tried to make wave energy a reality in the past, but as Greentech notes, many of their projects fell apart or ran out of money. But with renewed interest — and funding — in the industry, more companies are starting to test out their devices.

“We’re in that valley of death, climbing out of there at the moment,” naval architect Christopher Ridgewell, CEO of AW-Energy, a Finnish company working on a wave energy device called the WaveRoller, told Greentech.

Most of the exoplanets we’ve confirmed to date have never actually been seen directly. We confirm their presence by indirect means, such as the effect they have on their host star. But now, astronomers have revealed images of an indirectly found exoplanet.

It’s not just an impressive feat of skills and technology. The combination of methods has given us a superb toolkit for measuring an exoplanet. For the first time, astronomers have measured both the brightness and the mass of an exoplanet — which has given us a new probe into how planets form.

The exoplanet is Beta Pictoris c (β Pic c), a gas giant orbiting the star — you guessed it — Beta Pictoris, just 63 light-years away. It’s a very young, very bright star, around 23 million years old; as such, it’s still surrounded by a lot of dusty debris, and its exoplanets — we’ve confirmed two to date — are just babies, around 18.5 million years old.

A team of University of Arkansas physicists has successfully developed a circuit capable of capturing graphene’s thermal motion and converting it into an electrical current.

“An energy-harvesting circuit based on graphene could be incorporated into a chip to provide clean, limitless, low-voltage power for small devices or sensors,” said Paul Thibado, professor of physics and lead researcher in the discovery.

Continue reading “Physicists build circuit that generates clean, limitless power from graphene” »

One of the key challenges in developing effective, targeted cancer treatments is the heterogeneity of the cancer cells themselves. This variation makes it difficult for the immune system to recognize, respond to and actively fight against tumors. Now, however, new advances in nanotechnology are making it possible to deliver targeted, personalized “vaccines” to treat cancer.

A new study, published on October 2, 2020 in Science Advances, demonstrates the use of charged nanoscale metal-organic frameworks for generating free radicals using X-rays within tumor tissue to kill cancer cells directly. Furthermore, the same frameworks can be used for delivering immune signaling molecules known as PAMPs to activate the immune response against tumor cells. By combining these two approaches into one easily administered “vaccine,” this new technology may provide the key to better local and systemic treatment of difficult-to-treat cancers.

In a collaboration between the Lin Group in the University of Chicago Department of Chemistry and the Weichselbaum Lab at University of Chicago Medicine, the research team combined expertise from inorganic chemistry and cancer biology to tackle the challenging problem of properly targeting and activating an innate immune response against cancer. This work leveraged the unique properties of nanoscale metal-organic frameworks, or nMOFs —nanoscale structures built of repeating units in a lattice formation that are capable of infiltrating tumors.

But not anytime soon.

The nation’s newest military branch doesn’t currently launch anyone to the final frontier. But that will change someday, if all goes according to plan.

At Toyota, researchers are experimenting with prototypes that swoop from the ceiling to take care of chores with the help of machine learning.

A new, rare genetic form of dementia has been discovered by a team of Penn Medicine researchers. This discovery also sheds light on a new pathway that leads to protein build up in the brain—which causes this newly discovered disease, as well as related neurodegenerative diseases like Alzheimer’s Disease—that could be targeted for new therapies. The study was published today in Science.

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a buildup of proteins, called tau proteins, in certain parts of the brain. Following an examination of human brain tissue samples from a deceased donor with an unknown neurodegenerative disease, researchers discovered a novel mutation in the Valosin-containing protein (VCP) gene in the brain, a buildup of tau proteins in areas that were degenerating, and neurons with empty holes in them, called vacuoles. The team named the newly discovered disease Vacuolar Tauopathy (VT)—a neurodegenerative disease now characterized by the accumulation of neuronal vacuoles and tau protein aggregates.

“Within a cell, you have proteins coming together, and you need a process to also be able to pull them apart, because otherwise everything kind of gets gummed up and doesn’t work. VCP is often involved in those cases where it finds proteins in an aggregate and pulls them apart,” Edward Lee, MD, Ph.D., an assistant professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. “We think that the mutation impairs the proteins’ normal ability to break aggregates apart.”